TY - JOUR
T1 - Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters
AU - Peters, Solange
AU - Weder, Walter
AU - Dafni, Urania
AU - Kerr, Keith M.
AU - Bubendorf, Lukas
AU - Meldgaard, Peter
AU - O'Byrne, Kenneth J.
AU - Wrona, Anna
AU - Vansteenkiste, Johan
AU - Felip, Enriqueta
AU - Marchetti, Antonio
AU - Savic, Spasenija
AU - Lu, Shun
AU - Smit, Egbert
AU - Dingemans, Anne-Marie
AU - Blackhall, Fiona H.
AU - Baas, Paul
AU - Camps, Carlos
AU - Rosell, Rafael
AU - Stahel, Rolf A.
PY - 2014/11
Y1 - 2014/11
N2 - Introduction: The Lungscape project was designed to address the impact of clinical, pathological, and molecular characteristics on outcome in resected non-small- cell lung cancer (NSCLC). Materials and Methods: A decentralized biobank with fully annotated tissue samples was established. Selection criteria for participating centers included sufficient number of cases, tissue microarray building capability, and documented ethical approval. Patient selection was based on availability of comprehensive clinical data, radical resection between 2003 and 2009 with adequate follow-up, and adequate quantity and quality of formalin-fixed tissue. Results: Fifteen centers contributed 2449 cases. The 5-year overall survival (OS) was 69.6% and 63.6% for stages IA and IB, 51.6% and 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA and IIIB, respectively (p <0.001). Median and 5-year relapse-free survival (RFS) were 52.8 months and 47.3%, respectively. Distant relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% of patients. Based on multivariate analysis for the OS, RFS, and time to relapse, the factors significantly associated with all of them are performance status and pathological stage. Conclusion: The aim of this report is to present the results from Lungscape, the first large series reporting on NSCLC surgical outcome measured not only by OS but also by RFS and time to relapse and including multivariate analysis by significant clinical and pathological prognostic parameters. As tissue from all patients is preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, besides providing an overview of the molecular landscape of stage I to III NSCLC.
AB - Introduction: The Lungscape project was designed to address the impact of clinical, pathological, and molecular characteristics on outcome in resected non-small- cell lung cancer (NSCLC). Materials and Methods: A decentralized biobank with fully annotated tissue samples was established. Selection criteria for participating centers included sufficient number of cases, tissue microarray building capability, and documented ethical approval. Patient selection was based on availability of comprehensive clinical data, radical resection between 2003 and 2009 with adequate follow-up, and adequate quantity and quality of formalin-fixed tissue. Results: Fifteen centers contributed 2449 cases. The 5-year overall survival (OS) was 69.6% and 63.6% for stages IA and IB, 51.6% and 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA and IIIB, respectively (p <0.001). Median and 5-year relapse-free survival (RFS) were 52.8 months and 47.3%, respectively. Distant relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% of patients. Based on multivariate analysis for the OS, RFS, and time to relapse, the factors significantly associated with all of them are performance status and pathological stage. Conclusion: The aim of this report is to present the results from Lungscape, the first large series reporting on NSCLC surgical outcome measured not only by OS but also by RFS and time to relapse and including multivariate analysis by significant clinical and pathological prognostic parameters. As tissue from all patients is preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, besides providing an overview of the molecular landscape of stage I to III NSCLC.
KW - NSCLC
KW - TNM stage
KW - Surgery
KW - Patients' and pathological characteristics
KW - Outcome
U2 - 10.1097/JTO.0000000000000320
DO - 10.1097/JTO.0000000000000320
M3 - Article
C2 - 25436801
SN - 1556-0864
VL - 9
SP - 1675
EP - 1684
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 11
ER -